ID
45778
Beskrivning
Principal Investigator: Elaine A Ostrander, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001105 We collected DNA from fresh frozen prostate tumor samples and matched peripheral blood from 10 subjects with aggressive, Gleason score ≥8 disease. Tumor and normal samples were sequenced on the Illumina HiSeq 2000 to mean depths of 95.3X and 48.3X, respectively.
Länk
Nyckelord
Versioner (1)
- 2023-06-20 2023-06-20 - Chiara Middel
Rättsinnehavare
Elaine A Ostrander, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Uppladdad den
20 juni 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs001105 NHGRI-Mayo Clinic Whole Genome Sequencing of Aggressive Prostate Tumors
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for prostate tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, family history of prostate cancer, ages at diagnosis and at surgery, prostate specific antigen (PSA) at diagnosis, treatment prior to surgey, lymphadenectomy, pathology Gleason score, pathology primary and secondary Gleason grades, total number of lymph nodes examined, number of positive lymph nodes, and estimated tumor volume (cc).
- This sample attributes table contains sample IDs, analyte type, body site where sample was collected, tumor status, primary metastatic tumor, primary tumor location, DNA isolation method, sequencing platform, chemistry version, and name of the center which conducted genotyping.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for prostate tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, family history of prostate cancer, ages at diagnosis and at surgery, prostate specific antigen (PSA) at diagnosis, treatment prior to surgey, lymphadenectomy, pathology Gleason score, pathology primary and secondary Gleason grades, total number of lymph nodes examined, number of positive lymph nodes, and estimated tumor volume (cc).
- This sample attributes table contains sample IDs, analyte type, body site where sample was collected, tumor status, primary metastatic tumor, primary tumor location, DNA isolation method, sequencing platform, chemistry version, and name of the center which conducted genotyping.
C0680251 (UMLS CUI [1,2])
C3203027 (UMLS CUI [1,2])
C0470187 (UMLS CUI [1,3])
C4697670 (UMLS CUI [1,4])
C0033573 (UMLS CUI [1,5])
C1292533 (UMLS CUI [1,6])
C0229664 (UMLS CUI [1,7])
C0012854 (UMLS CUI [1,8])